1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,737 | 0,741 | 22:38 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 50,64 | -0,20 % | Novonesis (Novozymes A/S): Trading by management and close relations of management | ||
| GENMAB | 226,80 | -1,43 % | Genmab A/S: Capital Increase in Genmab as a Result of Employee Warrant Exercise | Company Announcement COPENHAGEN, Denmark; May 12, 2026 - Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,650 | -1,08 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,338 | +3,05 % | Mit guten Konzepten und Entspannung im Nahost-Konflikt voran! MustGrow, K+S, Evotec und Novo Nordisk im Fokus | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Was für eine Nachricht: Einigung zwischen USA und dem Iran - Märkte plus 2 % in nur 1 Minute! So schnell kann es gehen. Für Investoren... ► Artikel lesen | |
| VERICEL | 28,000 | -0,71 % | Vericel Corporation: Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,120 | -9,40 % | Moleculin Biotech, Inc.: Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits | Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 21,000 | 0,00 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,025 | +0,99 % | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions | DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of... ► Artikel lesen | |
| REGENXBIO | 8,476 | -2,86 % | Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm | New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed... ► Artikel lesen | |
| AKEBIA | 1,015 | +0,54 % | Akebia Therapeutics verfehlt Gewinnprognose für Q1 2026 - Aktie bricht ein | ||
| ZEVRA THERAPEUTICS | 9,400 | +2,17 % | Zevra outlines Celiprolol interim analysis trigger at 28 events while expanding MIPLYFFA access | ||
| FENNEC PHARMACEUTICALS | 5,750 | 0,00 % | Fennec Pharmaceuticals Inc: Fennec Pharma to release Q1 2026 results May 14 | ||
| CORVUS PHARMACEUTICALS | 13,425 | -0,04 % | Corvus Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CARTESIAN THERAPEUTICS | 7,050 | +5,22 % | Cartesian Therapeutics stock price target lowered to $25 by H.C. Wainwright on launch timing | ||
| NANOBIOTIX | 44,640 | +9,68 % | Nanobiotix S.A.: Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology | Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle("LNP")-delivered therapies related to rapid liver clearancePre-treatment... ► Artikel lesen |
SYNTHAVERSE SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,737 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.